首页> 外文OA文献 >Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer’s and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink
【2h】

Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer’s and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink

机译:可以将常用处方药重新用于预防或治疗阿尔茨海默氏症和其他神经退行性疾病吗?英国临床实践研究数据链接中的观察性队列研究协议

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Current treatments for Alzheimer's and other neurodegenerative diseases have only limited effectiveness meaning that there is an urgent need for new medications that could influence disease incidence and progression. We will investigate the potential of a selection of commonly prescribed drugs, as a more efficient and cost-effective method of identifying new drugs for the prevention or treatment of Alzheimer's disease, non-Alzheimer's disease dementias, Parkinson's disease and amyotrophic lateral sclerosis. Our research will focus on drugs used for the treatment of hypertension, hypercholesterolaemia and type 2 diabetes, all of which have previously been identified as potentially cerebroprotective and have variable levels of preclinical evidence that suggest they may have beneficial effects for various aspects of dementia pathology. We will conduct a hypothesis testing observational cohort study using data from the Clinical Practice Research Datalink (CPRD). Our analysis will consider four statistical methods, which have different approaches for modelling confounding. These are multivariable adjusted Cox regression; propensity matched regression; instrumental variable analysis and marginal structural models. We will also use an intention-to-treat analysis, whereby we will define all exposures based on the first prescription observed in the database so that the target parameter is comparable to that estimated by a randomised controlled trial. This protocol has been approved by the CPRD's Independent Scientific Advisory Committee (ISAC). We will publish the results of the study as open-access peer-reviewed publications and disseminate findings through national and international conferences as are appropriate.
机译:当前对阿尔茨海默氏症和其他神经退行性疾病的治疗仅具有有限的效果,这意味着迫切需要可能影响疾病发生和发展的新药物。我们将研究选择常用处方药的潜力,以此作为鉴定预防或治疗阿尔茨海默氏病,非阿尔茨海默氏病痴呆症,帕金森氏病和肌萎缩性侧索硬化症的新药的更有效和更具成本效益的方法。我们的研究将集中于用于治疗高血压,高胆固醇血症和2型糖尿病的药物,所有这些药物先前都已被确定具有潜在的脑保护作用,并且具有不同水平的临床前证据,表明它们可能对痴呆症病理学的各个方面都具有有益作用。我们将使用临床实践研究数据链(CPRD)的数据进行假设检验观察性队列研究。我们的分析将考虑四种统计方法,它们具有不同的建模混淆方法。这些是经过多变量调整的Cox回归;倾向匹配回归工具变量分析和边际结构模型。我们还将使用意向性分析,从而根据数据库中观察到的第一个处方定义所有暴露,以使目标参数与随机对照试验估计的参数相当。该方案已获得CPRD独立科学咨询委员会(ISAC)的批准。我们将以开放获取的同行评审出版物形式发表研究结果,并在适当的时候通过国家和国际会议传播研究结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号